Corcept Therapeutics PE ratio CORT

Share price divided by earnings per share over the last twelve months, since 2016.

Today, Oct 23, 2026: 204×
10-year median: 28.3×
Against its 10-year history: 94th; percentile: 0 is its lowest day, 100 its highest
10-year range: 8.4× to 291×
Peer median: 60.3×

Corcept Therapeutics' PE ratio is 204× as of Oct 23, 2026: a share price of $85.86 against $0.42 of earnings per share over the last twelve months.

That is above its ten-year median of 28.3×, higher than on 94% of days in the last ten years.

Over that time it ranged from 8.4× in Feb 2019 to 291× in Aug 2026.

The median for 10 large drugmakers of a similar size is 60.3×.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	204×	39.2×	291×
2025	93.9×	39.6×	100.0×
2024	41.6×	23.1×	48.2×
2023	40.1×	20.6×	40.4×
2022	20.3×	20.1×	31.5×
2021	23.9×	22.6×	33.0×
2020	29.4×	13.2×	30.6×
2019	17.1×	8.4×	22.8×
2018	10.9×	10.0×	86.6×
2017	62.3×	57.3×	244×
2016	182×	182×	243×

Against its peers

Companies in Drug Manufacturers - General nearest Corcept Therapeutics' size, closest first, today.

Company	PE ratio
CORTCorcept Therapeutics	204×
PTGXProtagonist Therapeutics	134×
TGTXTG Therapeutics	19.8×
BMRNBiomarin Pharmaceutical	151×
ALKSAlkermes plc.	115×
AMRXAmneal Pharmaceuticals	41.6×
JAZZJazz Pharmaceuticals	14.6×
LGNDLigand Pharmaceuticals	32.3×
KNSAKiniksa Pharmaceuticals International	79.1×
INDVIndivior Pharmaceuticals	12.4×
ARQTArcutis Biotherapeutics	142×
Peer median	60.3×

Where Corcept Therapeutics ranks

#41of 41Large drugmakers with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Corcept Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.